{ "completed": true, "status": "completed_original_source_reconciliation", "provider_mode": "Consensus Pro signed-in browser; observed output and citation link mappings", "queries": [ "https://consensus.app/search/childhood-vaccination-autism-risk/yh5e0JaNQSW0KIGv1VdLNQ/" ], "query_record_note": "Exact visible question/response retained privately in raw browser receipt.", "primary_comparison_count": 11, "primary_comparisons": [ { "pmid": "14519711", "doi": "10.1001/jama.290.13.1763", "source_type": "primary study report", "study_group": "PMID14519711", "access_depth": "abstract_metadata", "consensus_aspect": "Matched thimerosal formulation and dose comparison", "result_comparison": "Original abstract verifies 467450 children, about 2.99 million person-years, autism RR 0.85(CI 0.60–1.20) and dose slope per 25 micrograms0.98(CI 0.90–1.06). Provider's numerical outline agrees, but absence of an observed effect is finite-precision evidence, not a proof that every rare event is impossible. Our access was original abstract/status, not complete full text.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/14519711/", "source_examination_receipts": [ "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\examinations\\original-10-22-5000.json" ], "body_receipts": [] }, { "pmid": "30831578", "doi": "10.7326/M18-2101", "source_type": "primary study report", "study_group": "PMID30831578", "access_depth": "abstract_metadata", "consensus_aspect": "MMR cohort and predefined risk/timing groups", "result_comparison": "Original abstract verifies657461 children, adjustedHR 0.93(CI 0.85–1.02), no consistent increased risk in specified familial-risk/timing groups, and explicitly no individual chart review. Provider numbers agree; 'no subgroup vulnerability' must remain limited to tested definitions and their precision. Original access was abstract/status.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/30831578/", "source_examination_receipts": [ "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\examinations\\original-0-10-5000.json" ], "body_receipts": [] }, { "pmid": "42520244", "doi": "10.1097/INF.0000000000005349", "source_type": "primary study report", "study_group": "PMID42520244", "access_depth": "abstract_metadata", "consensus_aspect": "New age-landmark EHR study and negative-control interpretation", "result_comparison": "Original abstract verifies2,560,035 children, MMR aHR 0.97(99% CI 0.91–1.03) and pneumococcal negative-controlaHR 1.01(0.99–1.04). Provider's claim that this excludes residual confounding is rejected: it tests specified shared bias pathways and cannot exclude all unmeasured/measurement confounding. Original access was abstract/status; no body audit was claimed.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/42520244/", "source_examination_receipts": [ "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\examinations\\original-0-10-5000.json" ], "body_receipts": [] }, { "pmid": "11135778", "doi": "10.1001/jama.284.24.3145", "source_type": "primary study report", "study_group": "PMID11135778", "access_depth": "abstract_metadata", "consensus_aspect": "Actual original exemption and infection outcomes", "result_comparison": "Original abstract verifies Colorado exemption-associated measlesRR22.2 andpertussisRR5.9, plus community incidence/contact findings. Provider attached broad infection-protection claims to secondary reviews and unrelated Geier references rather than this requested original. The review uses the actual original and distinguishes nonrandom refusal/contact clustering from randomized efficacy. Original access was abstract/status.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/11135778/", "source_examination_receipts": [ "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\examinations\\original-34-44-5000.json" ], "body_receipts": [] }, { "pmid": "8538705", "doi": "10.1056/NEJM199602083340602", "source_type": "primary study report", "study_group": "PMID8538705", "access_depth": "abstract_metadata", "consensus_aspect": "Controlled pathogen prevention and real reactogenicity", "result_comparison": "Original abstract verifies randomized pertussis components versus DT-only control, product-specific clinical efficacy and higher whole-cell reactogenicity. This supplies actual intervention causality for the infection-risk branch and prevents a universal zero-adverse-effect framing. Original access was abstract/status, with linked erratum details unexamined.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/8538705/", "source_examination_receipts": [ "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\examinations\\original-44-54-5000.json", "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\examinations\\original-53-62-6000.json" ], "body_receipts": [] }, { "pmid": "34435933", "doi": "10.1080/21645515.2021.1959148", "source_type": "primary study report", "study_group": "VARICELLA_NCT00226499_PARENT", "access_depth": "abstract_metadata", "consensus_aspect": "Long-term prevention with a matched active control", "result_comparison": "Original abstract verifies randomized varicella-antigen schedules versus MMR-only control, ten-year confirmed-varicella protection and stronger two-dose efficacy. The Russian sample is a subset of one internationalNCT00226499 trial, not an extra independent trial. Original access was abstract/status.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/34435933/", "source_examination_receipts": [ "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\examinations\\original-53-62-6000.json", "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\examinations\\original-54-62-5000.json" ], "body_receipts": [] }, { "pmid": "16079072", "doi": "10.1289/ehp.7712", "source_type": "primary study report", "study_group": "PMID16079072", "access_depth": "full_text_partial", "consensus_aspect": "Blood clearance is not complete brain clearance", "result_comparison": "Original Results5–8 verify faster blood clearance after thimerosal than methylmercury but slower brain than blood clearance and retained inorganic mercury. Provider's shorter-half-life summary is incomplete if taken to mean no brain retention. These kinetic findings do not establish clinical autism; our access includes selected original body passages.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/16079072/", "source_examination_receipts": [ "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\examinations\\original-22-34-5000.json" ], "body_receipts": [ "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\body-presentation-receipts\\16079072-s1-p5-6-7-8.json" ] }, { "pmid": "19560158", "doi": "10.1016/j.jpeds.2009.04.011", "source_type": "primary study report", "study_group": "PMID19560158", "access_depth": "full_text_partial", "consensus_aspect": "Population-model pharmacokinetics and developmental scope", "result_comparison": "Original Methods0/1/7 show late-preterm infants at 32–37 weeks, vaccine exposure, one pre/post sample per infant and population-based half-life modeling. The abstract's6.3 dayestimate is not repeated individual serial kinetics, evidence for very-preterm infants, or an autism-incidence endpoint. Our access includes selected original Methods.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/19560158/", "source_examination_receipts": [ "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\examinations\\original-22-34-5000.json" ], "body_receipts": [ "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\body-presentation-receipts\\19560158-s0-p0-1-7.json" ] }, { "pmid": "19852790", "doi": "10.1186/1472-6904-9-17", "source_type": "primary study report", "study_group": "ADAMS_DMSA_PARENT", "access_depth": "full_text_partial", "consensus_aspect": "Chelation comparison and outcome hierarchy", "result_comparison": "Original Methods1/3–5 and Results14/20/26/28/30 show that every participant received initial active DMSA, with one-versus-seven-round randomization and no significant reported between-group symptom advantage. Both within-group changes and post-dose metal regressions cannot prove placebo-controlled efficacy or vaccine-caused autism. Part A(PMID 19852789) is the same trial, not an independent primary study; our access includes selected original body.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/19852790/", "source_examination_receipts": [ "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\examinations\\original-34-44-5000.json" ], "body_receipts": [ "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\body-presentation-receipts\\19852790-s1-p1-3-4-5.json", "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\body-presentation-receipts\\19852790-s2-p14-20-26-28-30.json" ] }, { "pmid": "26452420", "doi": "10.1016/j.jaci.2015.07.048", "source_type": "primary study report", "study_group": "PMID26452420", "access_depth": "full_text_partial", "consensus_aspect": "Specific true vaccine adverse-event ascertainment", "result_comparison": "Original Methods3/4/6 verify chart review, medical-officer Brighton adjudication and a per-dose denominator. The abstract reports33 cases/25,173,965 doses, or1.31 per million doses, across children/adults. Provider's general rare-adverse-event statement is strengthened with actual original evidence, while autism remains a separate outcome. Our access includes selected original Methods.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/26452420/", "source_examination_receipts": [ "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\examinations\\original-53-62-6000.json", "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\examinations\\original-54-62-5000.json" ], "body_receipts": [ "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\body-presentation-receipts\\26452420-s0-p3-4-6.json" ] }, { "pmid": "20587679", "doi": "10.1542/peds.2010-0665", "source_type": "primary study report", "study_group": "PMID20587679", "access_depth": "abstract_metadata", "consensus_aspect": "Formulation and age-specific seizure risk", "result_comparison": "Original abstract verifies first-doseMMRVversusseparate MMR plus varicella seizureRR1.98 andaboutoneexcessfebrileseizureper2300 doses in 12–23 month-olds. The older4–6 yearstudy(PMID 22473362) differs. This is an acknowledged safety boundary, not evidence for autism or a blanket avoidance policy. Original access was abstract/status.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/20587679/", "source_examination_receipts": [ "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\examinations\\original-53-62-6000.json", "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\examinations\\original-54-62-5000.json" ], "body_receipts": [] } ], "grade_changed": false, "grade_change_note": "Source-based adjudication; no independent blinded regrade claimed.", "raw_receipts": [ { "path": "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\vaccine-autism-avoidance\\consensus-browser-2026-10-12.json", "sha256": "a4e9a3a08482bb9070ab7a2b5f51173cba887da71300d89288ccae031d444cff" } ], "independent_blinded_audit": false, "cutoff": "2026-10-12", "completed_utc": "2026-10-12T21:01:18.571999+00:00", "conclusion": "Endpoint hierarchy, experimental scope and original-source limits determine the evidence cards; provider wording does not override them." }